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A complex relationship exists between tumourigenicity and
drug resistance. At diagnosis, many tumour cells appear to
be intrinsically more responsive to chemotherapeutic agents
than normal cells; however, upon clinical relapse, acquired
drug resistance appears limited to the tumour cells. This
problem in clinical oncology is difficult to study experiment-
ally because many multidrug-resistant (MDR) cell lines
developed in vitro prove to be non-tumourigenic in athymic
mice and to have a differentiated or 'normalized' phenotype
(Biedler & Peterson, 1981; Remy et al., 1984). This feature
unfortunately precludes the use of many MDR cell lines for
experimental investigations in immunodeficient animals.
It has been suggested that an increase in epidermal growth
factor receptor (EGFR) number may be associated with the
diminished oncogenic potential of MDR cell lines (Meyers et
al., 1986). EGFR is a well-characterised growth factor recep-
tor which stimulates cellular proliferation and differentiation
upon binding its ligand, epidermal growth factor (Carpenter,
1984). EGFR phosphorylates tyrosine residues, shares
sequence homology to the v-erbB transforming protein of the
avian erythroblastosis virus (Downward et al., 1984) and
may be up-regulated in the presence of the anti-tumour
antibiotic agent, doxorubicin (DOX) (Zuckier & Tritton,
1983). A possible link between EGFR and MDR would be of
interest for a better understanding of tumour cell growth and
transformation in human MDR cancers.
Gill et al. (1985) reported a close correlation between
chromosome 7 alterations and the synthesis of EGFR. Inter-
estingly, a similar association exists between chromosome 7
and the MDR phenotype (Slovak et al., 1987) as well as with
genes which control invasion and metastases of malignant
tumours (Collard et al., 1987). These data suggest that these
genes and perhaps other genes localised to chromosome 7
may act either alone or in concert in tumour cell progression.
In a previous study, we described the in vitro growth
characteristics and pharmacological properties of two human
multidrug resistant cell lines selected in DOX, HT1080/DR4
fibrosarcoma cells and LoVo/DR5 colon adenocarcinoma
cells (Slovak et al., 1987, 1988). Despite identical selection
strategies in vitro, the mechanism underlying the MDR
phenotype of these two cell lines differ. LoVo/DR5 cells
overexpress P-glycoprotein without gene amplification where-
as HT1080/DR4 are drug resistant by a mechanism indepen-
dent of P-glycoprotein (Slovak et al., 1988). Chromosome 7
alterations were present in both MDR-resistant sublines
(Slovak et al., 1987). Of interest, a putative homogeneously
staining region (HSR) of the short arm of chromosome 7
(p13-*.p22) was observed in HT1080/DR4 cells. This region
of 7p is coincident with the chromosomal locus of the EGFR
gene (Carlin & Knowles, 1982). These data suggested that
alterations in the EGFR might play a role in the acquired
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drug resistance of these two human MDR-resistant cell lines.
In the present study, we have (i) confirmed the lack of
P-glycoprotein in HTIO8O/DR4 cells by using a monoclonal
antibody, C494, which identifies a different epitope on P-
glycoprotein than the C219 monoclonal antibody used in our
previous study, (ii) determined the tumorigenic potential of
HT1O8O/DR4 cells, and (iii) determined if EGFR gene ampli-
fication or overexpression has occurred in either the HTIO80/
DR4 or LoVo/DR5 sublines.
To confirm our previous assertion that HTIO8O/DR4 cells
do not overexpress P-glycoprotein (Slovak et al., 1988),
immunoblot analysis using purified cell membrane compon-
ents and the C494 monoclonal antibody was performed.
Plasma membrane purification, protein determinations, and
immunoblotting procedures for the parental and DOX-resis-
tant sublines were as previously described (Slovak et al.,
1988). The blots were probed with 125I-labelled C494 mono-
clonal antibody (a gift from Dr V. Ling, Toronto, Canada).
A membrane preparation from the vinblastine-resistance
(VBL) subline of the CEM human lymphoblastic leukaemia
cell line, CEM/VBL,00, was used as a positive control (Beck
et al., 1979). The findings clearly confirmed that HTIO80/
DR4 cells do not overexpress P-glycoprotein, whereas CEM/
VBLIoo and LoVo/DR cells significantly overexpress this drug
resistant-related protein (Figure 1). These data are in agree-
ment with the molecular characterisation of these MDR-
resistant sublines (Slovak et al., 1988). Of interest, a faint
band which is readily apparent with a longer exposure, is
observed in the LoVo parental and the LoVo/DR4 revertant
subline maintained in drug-free (DF) medium over a 5 month
period, supporting the suggestion that some colon carcinoma
cells may be intrinsically resistant to chemotherapeutic agents
by virtue of expression of mdrl (Fojo et al., 1987).
To determine if the tumorigenic potential of HT1080 and
HT108O/DR4 cells differed, I07 cells suspended in 0.125 ml
phosphate buffered saline were injected subcutaneously in the
right flank of female BALB/c nude mice. For each experi-
ment, four mice per cell line were injected; the experiment
was repeated twice. Mice were monitored daily. Tumours
were measured in two dimensions and the area (mm2) was
calculated. Tumours from both HT1080 and the DOX resis-
tant HTlO8O/DR4 subline were observed within 2 to 4 weeks
(Table I). The gross morphological appearance of the
tumours differed; tumours derived from the HTIO8O/DR4
cells were small and firm whereas the HT1080 parental cell
tumours were large and much softer in consistency. This
observation is in keeping with the morphological changes
noted in vitro during the acquisition of drug resistance; that
is, the slender, spindle-shape appearance of HT1080 com-
pared to the polyglonal and distorted forms of HTIO8O/DR4
cells. The longer latency period and slower growth of the
HT1O8O/DR4 tumours is consistent with both the morpho-
logical changes and its longer doubling time in vitro (HtIO80,
19 h; HT1080/DR4, 30 h) (Slovak et al., 1987). Although the
data may suggest a degree of difference in the tumourigenic
potential which may be attributed to the 'lower' level of drug
resistance compared to other reported studies (Meyers et al.,
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Figure I Western blot analysis of plasma membrane compon-
ents. Nitrocellulose blots were probed with the C494 monoclonal
antibody to P-glycoprotein. Fifty tLg of membrane protein were
loaded in each lane. LoVo/DR4 (129-fold DOX-resistant) and
LoVo/DR5 (285-fold DOX-resistant) cells overexpress P-glyco-
protein whereas HT1080/DR4 (222-fold DOX-resistant) cells do
not appear to overexpress the drug-resistant associated glyco-
protein. LoVo/DR4-DF is a revertant subline of LoVo/DR4
maintained in drug-free medium for 5 months. Note that a faint
band is present in both parent and LoVo/DR4-DF lanes. CEM/
VBLIoo cells were used as a positive control. Ordinate, molecular
weight in thousands, kDa.
Table I Tumorigenicity of HT1080 and HT1080/DR4 sublines in
BALB/c nude mice
No ofcells Tumours Mean latency Mean tumour
Cell line inoculateda formed period (days) size (mm2)b
HT1080 I x 107 8/8 14±3 211±74
HT1080/DR4 1 x 107 5/7C 23±8d 70± 16d
'Four mice wereinjected/experiment. Results are from two indepen-
dent experiments.b10 days after the tumours became detectable,
measurements in twodimensions weremadetocalculatethearea(mm2).
Values, mean±s.d. c One mouse died with no tumour before the mean
latency period and was therefore not included. Two mice failed to
develop tumours by day 68. dSignificantly different from HT1080
(P<0.01, Mann-Whitney U test).
1986, 1988), the 220-fold HTIO80/DR4 cells are considered
'highly' resistant in terms of clinical applicability and there-
fore any minor alterations in the tumourigenic potential are
most likely not directly related to the MDR human cancers.
To determine if the EGFR expression was altered by either
gene amplification or overexpression, high molecular weight
DNA and total cellular RNA were isolated by standard
methods (Maniatis et al., 1982) from HT1080, HT1O8O/DR4,
LoVo and LoVo/DR5. Controls included the A431 cell line
which has amplified and overexpressed EGFR (Merlino et
al., 1984) and the CEM parental and CEM/VBL,oo variant
that lacks EGFR overexpression/gene amplification, the lat-
ter containing amplified P-glycoprotein gene sequences (Hill
et al., 1988). For Southern (1975) blotting, 10 g of DNA
from the various cell lines was digested with EcoRI, electro-
phoretically fractionated in 0.9% agarose gels, transferred to
Gene Screen Plus (New England Nuclear) and hybridized to
the cDNA pE7 probe which codes for a portion of the
EGFR gene and is highly homologous to a portion of the
v-erbB oncogene (Merlino et al., 1984). Hybridisations and
washings were performed under high-stringency conditions.
RNA dot blots were performed as described by Thomas
(1980) by applying RNA from each cell line onto nitrocellu-
lose using a minifold apparatus (Schleicher and Schuell). For
quantitation of the EGFR mRNA, serial dilutions of RNA
were applied to Gene Screen Plus using a slot blot apparatus
(BioRad) and hybridised with the pE7 probe. To control for
variations in RNA loading, the blots were stripped and
reprobed with a human actin cDNA probe.
The results of the EGFR Southern and RNA dot blots are
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Figure 2 EGFR gene amplification and mRNA expression. a,
Southern blot hybridisation. EcoRI digested DNA from parental
and DOX-resistant cell lines were hybridised to pE7, a human
cDNA probe for the EGF receptor gene. CEM and CEM/VBL,OO
served as negative controls; A431 cells have amplified EGFR
genes. b, EGFR mRNA expression. Total cellular RNA from
parental and DOX-resistant cell lines (0.625 jig ml-') was applied
to nitrocellulose and hybridised to the EGFR cDNA probe, pE7.
CEM, negative control; A431, positive control. The blot was
stripped and reprobed with actin.
presented in Figure 2. Comparison of the DOX-resistant
lines with their respective parental cell line demonstrates no
EGFR gene amplification or significant mRNA overexpres-
sion in HT1080/DR4 and LoVo/DR5 cells. Although these
data support the lack of EGFR gene amplification as pre-
viously described (Meyers et al., 1988), these data fail to
strengthen the extensive EGFR investigation of MDR-resis-
tant human neuroblastoma cells with elevated EGFR levels
resulting specifically from overexpressed EGFR mRNA
(Meyers et al., 1988). Furthermore, to rule out the possibility
of elevated EGFR levels which may exist without increased
mRNA levels (e.g., decreased protein turnover),'251I-EGF
receptor binding assays were performed as described (Honeg-
ger et al., 1987). The EGF binding activity did not differ
between the parental cells and their respective multidrug
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resistant sublines ['25I-EGF bound (% of total) per 106 cells;
HT1080, 1.93 ± 0.25%; HT1080/DR4, 1.72 ± 0.11%; LoVo,
0.53 ± 0.04%; LoVo/DR5, 0.63 ± 0.08%; all results are
mean ± s.d. of three experiments].
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Figure 3 Quantitation of EGFR mRNA. Serial dilutions of total
cellular RNA from sensitive and DOX-resistant cell lines were
applied to nylon membranes using a slot blot apparatus and
hybridised with the EGFR cDNA probe, pE7. Autoradiographs
were analysed with a Hoefer GS300 scanning densitometer and
only values from the linear-response range of the film were used.
Blots were stripped ard reprobed with a human cDNA probe to
control for RNA loading. Ratios of pE7 to actin bands were
standardised to the CEM control which was assigned a value of
1. The bars show the means of three independent RNA extrac-
tions.
In summary, our results indicate that while the cellular
morphology of the HT1080/DR4 fibrosarcoma subline
changed with the development of drug resistance, these cells
retained their ability to form tumours in immunodeficient
mice without a concomitant alteration of EGFR and despite
the presence of a putative HSR near the normal cellular
locus for EGFR on the short arm of chromosome 7.
Although the relationship between drug resistance and
tumourigenicity remains unclear, these data and those of
others (Miyamoto, 1986; Mirski et al., 1987; Hill et al., 1988)
support the idea that drug resistance and the loss of
tumourigenicity should be regarded as two independent
events (Remy et al., 1984).
Several biochemi&al mechanisms in addition to P-glyco-
protein have been proposed to explain the MDR phenotype.
These include quantitative or qualitative alterations of DNA
topoisomerase II, DNA repair enzymes and the drug-meta-
bolising enzymes, acting either singly or in concert to mani-
fest drug resistance. Identification and characterisation of the
individual as well as the synergistic aspects of resistance
mechanisms will be essential in the elucidation of clinical
drug resistance. The present findings, and the inability of
common chemosensitising agents (e.g. verapamil, nicardipine)
to circumvent the drug resistance of HT1080/DR4 (Cole et
al., 1989), indicate that HT1080/DR4 will be a valuable
model system of non-P-glycoprotein mediated drug resistance
for both in vitro as well as in vivo experimental therapeutic
investigations.
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